All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
The Psoriasis and Psoriatic Arthritis Hub was pleased to speak with Paolo Gisondi, University Hospital of Verona, Verona, IT. We asked, How does deucravacitinib fit into the treatment landscape for plaque psoriasis?
How does deucravacitinib fit into the treatment landscape for plaque psoriasis?
Gisondi discusses the benefit of oral therapies, such as deucravacitinib, as a more convenient and patient-friendly treatment option than injectable treatments. He highlights that injectable therapies can be intimidating for patients who are starting a new systemic treatment, then goes on to discuss the efficacy and, in particular, the safety benefit of deucravacitinib due to its allosteric inhibition of tyrosine kinase 2 (TYK2), when compared with Janus kinase (JAK) inhibitors. He emphasizes the reduced risk of infections, such as upper respiratory tract infections or nasopharyngitis, in patients treated with deucravacitinib vs JAK inhibitors. Finally, he discusses the potential of deucravacitinib in patients with psoriasis with characteristics of eczema, and in patients who had paradoxical eczema reactions to interleukin-17 (IL-17) inhibitors.
Agree
%
Disagree
%
This educational resource is independently supported by Bristol Myers Squibb. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox